CLL | Tumor

Imbruvica-Venclexta Combo Superior to Chlorambucil-Obinutuzumab for CLL

June 16th 2021

The combination of Imbruvica with Venclexta significantly reduced the risk for progression or death by 78% compared with chlorambucil plus obinutuzumab.

Front-Line Imbruvica-Venclexta Combo May Induce Durable Responses in Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma

June 10th 2021

Treatment with this combination was associated with encouraging clinical responses in this patient population.

Calquence and Imbruvica Elicit Similar Survival Results in Previously Treated Patients with Type of Leukemia

June 8th 2021

Although survival rates were similar, patients with chronic lymphocytic leukemia treated with Calquence experienced fewer side effects than those who received Imbruvica.

Cirmtuzumab Plus Imbruvica Led to Increased Response Rates in MCL and CLL

June 7th 2021

Cirmtuzumab plus Imbruvica led to an 83.3% overall response rate, with 38.9% complete response and 44.4% partial response rate, in patients with mantle cell lymphoma and chronic lymphocytic leukemia.

Keep Inspiring

April 28th 2021

Don’t let your disease define you

Imbruvica Plus Ublituximab Safely Improves Response Rate for High-Risk Chronic Lymphocytic Leukemia

April 23rd 2021

Imbruvica combined with ublituximab improved overall response rate and progression-free survival for relapsed/refractory high-risk chronic lymphocytic leukemia with minimal residual disease negativity.

Gazyva With Chemotherapy Shows Promise for Chronic Lymphocytic Leukemia

April 22nd 2021

Final analysis of a phase 3 study demonstrates a tolerable toxicity profile for Gazvya in combination with chemotherapy for patients with ether first-line or relapsed/refractory chronic lymphocytic leukemia.

Your Chronic Lymphocytic Leukemia (CLL) Diagnosis

April 16th 2021

Navigating life with blood cancer

Sponsored Content: CALQUENCE® (acalabrutinib) for Patients with Chronic Lymphocytic Leukemia (CLL)

March 17th 2021

An interview with Dr. Jennifer K. Lue, Assistant Professor of Medicine, Center for Lymphoid Malignancies, Division of Hematology and Oncology, Columbia University Irving Medical Center.

Imbruvica Plus Novel Agent May Improve Progression-Free Survival in Chronic Lymphocytic Leukemia

March 3rd 2021

Patients treated with Imbruvica plus TG-1101 had an overall response rate of 83% compared with 65% in those treated with Imbruvica alone.

Marialice’s Story with Chronic Lymphocytic Leukemia (CLL)

February 19th 2021

Treating CLL with CALQUENCE® (acalabrutinib)

First Patient to Receive CAR-T Cell Therapy Dies, Cancer Organizations Appeal to President Biden for COVID-19 Vaccine Priority Access, and More

February 19th 2021

From the death of Bill Ludwig, the first patient to receive CAR-T cell therapy to treat his end-stage CLL, to a letter to the President urging him to grant patients with cancer and survivors priority access to the COVID-19 vaccine, here’s what’s happening in the cancer space this week.

Jim’s Story with Chronic Lymphocytic Leukemia (CLL)

February 19th 2021

Treating CLL with CALQUENCE® (acalabrutinib)

Adding to the Regimen: NCCN Updates in Leukemia and Lymphoma

February 15th 2021

The NCCN has updated its recommendations for chronic lymphocytic leukemia and small lymphocytic lymphoma to now include Brukinsa as a first- and second-line therapy in a subgroup of patients.

Addressing Unmet Needs in CLL

February 2nd 2021

CLL: An Early Clinical Trial With Ibrutinib

February 2nd 2021

CAR T-Cells: Refining CLL Therapy With Clinical Trials

February 2nd 2021

CLL Versus Other Leukemia Types

February 2nd 2021

CLL Society: Smart Patients Get Smart Care

February 1st 2021

Treatment Options in Relapsed CLL

February 1st 2021

Initiating Therapy in CLL

February 1st 2021

Options for Managing Refractory CLL

February 1st 2021

Predicting Response to Therapy in CLL

February 1st 2021

CLL: A Cancer of the Blood

February 1st 2021

Patient Perspectives on the CLL Treatment Paradigm

February 1st 2021

A Diagnosis of Chronic Lymphocytic Leukemia With ITP

February 1st 2021

Significance of Watch-and-Wait Approach in CLL

February 1st 2021

Why It's an Exciting Time for Patients With CLL

January 31st 2021

For Younger Patients, CAR T-Cell Therapy Could Play a Role in CLL Treatment

January 18th 2021

In an interview, Dr. Matthew Davids of the Dana-Farber Cancer Institute discusses the future of CAR T-Cell therapy in the treatment of younger patients with chronic lymphocytic leukemia.

Areas Patients with CLL Can Focus On to Maintain Their Health Beyond Treatment

January 15th 2021

In a recent interview with CURE®, a medical oncologist from the Dana-Farber Cancer Institute discussed why it’s important for patients with CLL, regardless of their treatment plans, to keep up on vaccinations and maintain a regular cancer screening schedule.